Latest Australian Biotech News

Page 3 of 4
Prescient Therapeutics has secured FDA Fast Track designation for PTX-100 in treating relapsed Cutaneous T-Cell Lymphoma and dosed the first patient in its Phase 2a trial, supported by a recent $6.8 million capital raise.
Ada Torres
Ada Torres
30 July 2025
Noxopharm Limited has successfully completed the first low-dose cohort in its HERACLES clinical trial for SOF-SKN™, clearing the way for higher dose testing in autoimmune disease treatment.
Ada Torres
Ada Torres
28 July 2025
Bio-Gene Technology Limited has completed the second tranche of its share placement, securing approximately A$2.46 million and issuing unlisted options to investors and its lead manager.
Ada Torres
Ada Torres
21 July 2025
Terragen Holdings has been granted a US patent for its microbial feed supplements, reinforcing its position in the animal probiotics market and supporting plans for US market entry.
Ada Torres
Ada Torres
3 July 2025
Prescient Therapeutics has opened a Share Purchase Plan to raise up to $7 million, offering shareholders discounted shares to fund the Phase 2 development of its targeted cancer therapy PTX-100.
Ada Torres
Ada Torres
2 July 2025
EVE Health Group has launched a $1.5 million capital raise alongside the acquisition of biotech firm Nextract, aiming to expand its footprint in health and pharmaceutical products focused on erectile dysfunction and period pain.
Victor Sage
Victor Sage
11 June 2025
Noxopharm’s Sofra™ technology has received promising external validation from BioRay Pharmaceutical, confirming its targeted anti-inflammatory potential and broad applicability in autoimmune disease therapies.
Ada Torres
Ada Torres
11 June 2025
Patrys Limited has raised $358,362 through a share placement and announced significant board changes, including the appointment of Dr Anton Uvarov and Mr Peter Christie, alongside making the CEO role redundant.
Ada Torres
Ada Torres
10 June 2025
EVE Health Group has initiated stability testing for its novel oral treatments targeting erectile dysfunction and dysmenorrhea, marking a crucial step toward regulatory approval in Australia. The company also finalizes its acquisition of Nextract, the developer behind these innovative formulations.
Ada Torres
Ada Torres
2 June 2025
Noxopharm has secured ethics approval to commence the HERACLES trial, marking the first human study of its novel SOF-SKN™ drug aimed at chronic inflammatory diseases.
Ada Torres
Ada Torres
29 May 2025
Island Pharmaceuticals has raised $3.6 million through a strategic share placement to advance its lead antiviral drug ISLA-101’s clinical development and broaden its asset portfolio ahead of pivotal Phase 2a/b trial results.
Ada Torres
Ada Torres
21 May 2025
Noxopharm Limited has raised nearly $2.5 million by selling its entire stake in Nyrada Inc, providing non-dilutive capital to advance its HERACLES clinical trial and expand its research pipeline.
Ada Torres
Ada Torres
20 May 2025